Mirum’s Livmarli becomes first FDA approved ALGS therapy
Category: #headlines  | By Mateen Dalal  | Date: 2021-10-02 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Mirum’s Livmarli becomes first FDA approved ALGS therapy

California-based Mirum Pharmaceuticals Inc. has reportedly announced that its drug, Livmarli (Maralixibat) has become the first U.S. FDA approved therapy for treating itching (cholestatic pruritus) in patients suffering from Alagille Syndrome (ALGS), a rare liver disease.

For the unversed, ALGS is a genetic disease wherein bile ducts are abnormally malformed,  narrow, and low in number, leading to bile accumulation in the liver.

The drug developed by Mirum Pharma blocks an important bile acid transport (iBAT) protein on the surface of the small intestine which helps in removal of bile acid from the human body through feces. Besides the functioning, the drug’s approval comprises information regarding side effects, including changes in liver tests which are often an indication of liver injury.

The drug would supposedly be made available for distribution immediately under the brand name Livmarli and will be priced at approximately USD 1,550 per unit. The annual cost of drug administration for a child weighing over 17 kg (37.4 pounds) is estimated to be around USD 391,000.

According to sources, the closest competitor for Livmarli is Albireo Pharma's Bylvay, which is currently in its late-stage testing. In July, Bylvay received the U.S. FDA’s approval for treatment of another liver disease called Progressive Familial Intrahepatic Cholestasis (PFIC), with pricing of USD 385,000 a year.

Chief Executive Officer of Mirum Pharmaceuticals, Chris Peetz, was quoted saying that itching is really devasting for children and families dealing with Alagille Syndrome and is the driving factor for potential liver transplant decisions.

Experts reportedly said that Livmarli could amass USD 400 million in sales by 2030, while analysts from Mirum expect a substantially higher market opportunity of USD 500 million for the indication.

The dosage for Livmarli will be determined by physicians as per the patient’s weight, cited sources with reliable information.

Source credit: https://www.usnews.com/news/us/articles/2021-09-29/mirums-oral-drug-becomes-first-us-approved-alagille-syndrome-therapy

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Hyundai Motor Company & Advent sign JDA to develop fuel cell technology

Hyundai Motor Company & Advent sign JDA to develop fuel cell technology

By Mateen Dalal

Hyundai Motor Company and Advent Technologies have entered into a joint development agreement, following the assessment of Advent’s Proprietary Membrane Electrode Assembly (MEA) technology. The evaluation was focused on the ability of Advent&rs...

Intellect chooses IHH Healthcare to devise mental health programs

Intellect chooses IHH Healthcare to devise mental health programs

By Mateen Dalal

Intellect, a leading mental health platform located in Singapore, has reportedly announced a partnership with IHH Healthcare, which is Asia’s largest private healthcare group. The main objective of the partnership is to introduce and customize ...

Dyson compensates employees with onetime payment in absence of bonus

Dyson compensates employees with onetime payment in absence of bonus

By Mateen Dalal

Dyson, a British company renowned for its innovative vacuum cleaners, hair dryers and other products, is reportedly offering a majority of the staff at its Singapore headquarters a one-time payment, in recognition of their exceptional contribution. ...